BR0209386A - Derivados de sulfonamida - Google Patents

Derivados de sulfonamida

Info

Publication number
BR0209386A
BR0209386A BR0209386-3A BR0209386A BR0209386A BR 0209386 A BR0209386 A BR 0209386A BR 0209386 A BR0209386 A BR 0209386A BR 0209386 A BR0209386 A BR 0209386A
Authority
BR
Brazil
Prior art keywords
sulfonamide derivatives
derivatives
bradykinin
pharmaceuticals
diseases
Prior art date
Application number
BR0209386-3A
Other languages
English (en)
Inventor
Terance William Hart
Timothy John Ritchie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0209386A publication Critical patent/BR0209386A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

"DERIVADOS DE SULFONAMIDA". A invenção refere-se a derivados de sulfonamida da fórmula I, onde R^ 1^-R^ 6^ são como definidos na descrição, processos para sua produção, seu uso como produtos farmacêuticos, particularmente para uso no tratamento ou prevenção de doenças, nas quais a ativação do receptor de bradicinina B~ 1~, desempenha uma função ou está envolvida, e composições farmacêuticas compreendendo-os.
BR0209386-3A 2001-05-14 2002-05-13 Derivados de sulfonamida BR0209386A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29082701P 2001-05-14 2001-05-14
PCT/EP2002/005240 WO2002092556A1 (en) 2001-05-14 2002-05-13 Sulfonamide derivatives

Publications (1)

Publication Number Publication Date
BR0209386A true BR0209386A (pt) 2004-07-06

Family

ID=23117717

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209386-3A BR0209386A (pt) 2001-05-14 2002-05-13 Derivados de sulfonamida

Country Status (13)

Country Link
US (1) US7109203B2 (pt)
EP (1) EP1389183B1 (pt)
JP (1) JP4150597B2 (pt)
CN (1) CN1268610C (pt)
AR (1) AR035891A1 (pt)
AT (1) ATE459598T1 (pt)
BR (1) BR0209386A (pt)
CA (1) CA2443721A1 (pt)
DE (1) DE60235536D1 (pt)
ES (1) ES2340664T3 (pt)
PE (1) PE20021158A1 (pt)
PT (1) PT1389183E (pt)
WO (1) WO2002092556A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
EP1524984A1 (en) * 2002-07-29 2005-04-27 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
CA2509881A1 (en) * 2002-12-19 2004-07-08 Elan Pharmaceuticals, Inc. Substituted n-phenyl sulfonamide bradykinin antagonists
KR20070083714A (ko) * 2004-10-20 2007-08-24 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 아데노신 수용체 작용제의 용도
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
PL1989214T3 (pl) 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
WO2008063712A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
WO2008028140A1 (en) * 2006-09-01 2008-03-06 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
ES2524259T3 (es) * 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
JP2012504147A (ja) * 2008-09-29 2012-02-16 ギリアード サイエンシーズ， インコーポレイテッド 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびＡ−２−α受容体作動薬の組み合わせ
EP2316820A1 (en) 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
DK2813502T3 (en) * 2013-06-14 2017-02-27 Dompé Farm S P A Bradykinin receptor antagonists and pharmaceutical compositions containing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE120047C (pt) *
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
EP1190710A4 (en) * 1999-05-13 2003-04-02 Shionogi & Co PREVENTIVE OR THERAPEUTIC MEDICATIONS FOR DIABETES
GB9913079D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2002092556A1 (en) 2002-11-21
DE60235536D1 (de) 2010-04-15
US7109203B2 (en) 2006-09-19
AR035891A1 (es) 2004-07-21
CA2443721A1 (en) 2002-11-21
ATE459598T1 (de) 2010-03-15
JP2004528385A (ja) 2004-09-16
PE20021158A1 (es) 2003-03-03
CN1268610C (zh) 2006-08-09
ES2340664T3 (es) 2010-06-08
US20040127533A1 (en) 2004-07-01
CN1509269A (zh) 2004-06-30
EP1389183B1 (en) 2010-03-03
EP1389183A1 (en) 2004-02-18
JP4150597B2 (ja) 2008-09-17
PT1389183E (pt) 2010-04-26

Similar Documents

Publication Publication Date Title
BR0209386A (pt) Derivados de sulfonamida
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
BR0208338A (pt) Derivados de piridina
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0607583A2 (pt) derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
BR0210358A (pt) Inibidores da protease de hiv, composições contendo os mesmos, seus usos farmacêuticos e materiais para sua sìntese
BR9803880A (pt) Derivados de pirazol, sua preparação e seu emprego em medicamentos.
BR0316680A (pt) Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
BRPI0413616B1 (pt) 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BR0015315A (pt) Compostos, medicamentos, composições farmacêuticas, utilização de compostos e produtos industriais
BRPI0511874A (pt) derivados da pirrolopiridina
BR0017050A (pt) Oxazolidinonas suebstituìdas e seu emprego na área da coagulação do sangue
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
SE0300456D0 (sv) Novel compounds
DE60214569D1 (de) Harnstoffverbindungen mit antiproteolytischer wirkung
NO20075637L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater som medikamenter for behandling av infertilitet
BR0213037A (pt) Derivados de pirimidina
SE0303480D0 (sv) Benzofuranes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.